Search Results

Agilent Technologies Inc., a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego, one of the top-ranked public research universities in the world, announced an innovative scientific collaboration to establish the Agilent Center of Excellence in Cellular Intelligence.

CorDx announced a transformative $21M gift to the University of California San Diego’s Jacobs School of Engineering from CorDx founder Aiiso Yufeng Li, with support from members of the CorDx family – Li’s wife, Aiiso DongDong Li, Mac Chen, Haixia Yang, Monica Hu, and others at CorDx.

Looking for a biotech job in San Diego? Check out these seven top companies hiring life sciences professionals like you.

While San Diego remains a top biotech hub behind Boston and San Francisco, the city—which hosts this week’s BIO International Convention—has seen employment drop amid economic headwinds.

Looking for a biopharma job in San Diego? Check out these top five companies hiring life sciences professionals like you.

Debiopharm today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.

Humanetics Corporation is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization International Convention in San Diego, CA next week.

Elastin Biosciences today announced its participation in this year’s 2024 BIO International Convention, which is being held in San Diego, CA , June 3-6, 2024.

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, detailed data presented by its partners at the University of California, San Francisco on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470.